ALERT - THIS PROTOCOL IS LINKED TO 2020-0655 (GU STUDY)Phase 1/2, First-In-Human, Multi-Part, Open- Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a monotherapy and in combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
MD Anderson Study Status
This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with nivolumab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Solid Tumor, Melanoma, Renal Cell Carcinoma, Urothelial Carcinoma, Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Gastric Cancer, Ovarian Cancer, Prostate Cancer, Triple Negative Breast Cancer, Endometrial Cancer
Melanoma Medical Oncology
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.